NCT00865111View on ClinicalTrials.gov

A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

April 30, 2006

Study Completion Date

April 30, 2006

Conditions
Healthy
Interventions
DRUG

Bupropion 150 mg Extended-Released Tablet, single dose

A: Experimental Subjects received Abrika formulated products under fasting conditions

DRUG

Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose

B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions

Trial Locations (1)

33901

SFBC Ft. Myers, Inc., Fort Myers

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
lead

Actavis Inc.

INDUSTRY

NCT00865111 - A Relative Bioavailability Study of Bupropion Sustained Release 150 mg Tablets Under Fasting Conditions | Biotech Hunter | Biotech Hunter